Growing up, like every normal 10-year-old, my biggest fear was failure. I'd look at all your slightly shocked and sat slightly confused faces and think, "Maybe this wasn't as common as a fear as I thought." You have to understand that I was as type A as they came. I was the type of kid that needed to organize her toys before playing with them.I had built so much of my identity on my grades and my accomplishments, whether or not I got the highest grades, whether or not I won the best competitions. I mean, th ...

RT sarah (@sahouraxo)BREAKING:Trump and Israel dropped bombs on one of the oldest scientific institutions in the region.A medical research center in the heart of Iran’s capital, Tehran.They’re not bombing a battlefield.They’re bombing science.They’re bombing medicine.They’re bombing history. https://t.co/Cu3RYORp7w ...

Daniel Nadler cofounded OpenEvidence in 2022 to use AI to help doctors make sense of the voluminous amount of medical research.OpenEvidence has reached a valuation of $12 billion after an early 2026 funding round. Nadler owns nearly 60% of the company.See where he lands on the 2026 #ForbesBillionaires list: https://t.co/JYn52gRk2z (Photo: Mauricio Candela for Forbes) ...

Daniel Nadler cofounded OpenEvidence in 2022 to use AI to help doctors make sense of the voluminous amount of medical research.OpenEvidence has reached a valuation of $12 billion after an early 2026 funding round. Nadler owns nearly 60% of the company.See where he lands on the 2026 #ForbesBillionaires list: https://t.co/JYn52gRk2z (Photo: Mauricio Candela for Forbes) ...

Core Viewpoint - Tempus AI, Inc. has announced a strategic collaboration with Blood Cancer United to develop a patient-centered registry for pediatric acute myeloid leukemia, aiming to enhance precision medicine in this area [1] Company Summary - Tempus AI, Inc. is a technology company focused on advancing precision medicine through the adoption of artificial intelligence [1] - Blood Cancer United, formerly known as The Leukemia & Lymphoma Society, is the largest global nonprofit dedicated to supporting blood cancer patients, conducting research, and advocating for the community [1] Industry Summary - The collaboration targets pediatric acute myeloid leukemia (pAML), which is identified as a rare and aggressive form of blood cancer [1]

“The most plausible explanation for a subset of these [Havana Syndrome] cases was a form of radiofrequency or microwave energy,” says Dr. David Relman, a Stanford University professor of medicine who led two expert panels on Havana Syndrome. #havanasyndrome #braininjury ...

Good morning. At age nine with my friends, we used to braid friendship bracelets. We would sit at my kitchen table after school and on the weekends with a beautiful bag of string of all colors and sit together and braid friendship bracelets.At the time, it was a simple hobby. It was something that brought us together. But this hobby became something bigger when we began to sell these friendship bracelets to raise money for cancer research.We got together as a team for our local Relay for Life chapter of the ...

Core Viewpoint - The Meridian Hedged Equity Fund's fourth-quarter 2025 performance was influenced by optimism regarding monetary easing and concerns about economic growth and valuations, with a modest gain of 0.08% compared to the S&P 500 Index's 2.66% return and the CBOE S&P 500 BuyWrite Index's 6.53% return [1] Group 1: Fund Performance - In Q4 2025, the Fund gained 0.08%, while the S&P 500 Index returned 2.66% and the CBOE S&P 500 BuyWrite Index returned 6.53% [1] - The Fund's performance contributed positively to robust annual results despite a cooling market sentiment later in the quarter [1] Group 2: Danaher Corporation (NYSE:DHR) - Danaher Corporation was highlighted as a key contributor to the portfolio performance, with a market capitalization of $150.16 billion [2][4] - The stock closed at $212.58 per share on February 13, 2026, with a one-month return of -9.92% and a twelve-month return of 3.04% [2] - Danaher is recognized for its strong presence in life sciences and diagnostics, particularly in bioprocessing, medical research, and clinical diagnostics [3] Group 3: Investment Insights - The Fund holds Danaher for its competitive positioning in growing end-markets and consistent free cash flow generation, with management reaffirming forward guidance [3] - In 2025, Danaher reported sales of $24.6 billion and core revenue growth of 2% [4] - Despite recognizing Danaher's potential, the Fund suggests that certain AI stocks may offer greater upside potential and less downside risk [4]

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as a strong investment opportunity in the medical research sector, particularly highlighted by hedge funds [1] - The company reported promising results from the OMNY-AF study, achieving 100% acute procedural success and 90% primary effectiveness at 12 months for the OMNYPULSE Platform [1] - RBC Capital and BofA have both raised their price targets for JNJ shares, indicating positive market sentiment and expectations for growth [2][3] Group 1: Study Results - The OMNY-AF study showed that 100% of procedures were successful with no adverse events reported [1] - 56.7% of cases were performed without fluoroscopy, showcasing advancements in procedural techniques [1] - 90% of patients achieved primary effectiveness at the 12-month mark, indicating strong long-term outcomes [1] Group 2: Market Sentiment and Price Targets - RBC Capital increased its price target for JNJ from $240 to $255 while maintaining an Outperform rating, reflecting confidence in the company's financial position despite ongoing litigation [2] - BofA raised its price target from $221 to $227, suggesting a higher blended P/E multiple and expectations for organic growth in both MedTech and pharmaceuticals [3] Group 3: Company Overview - Johnson & Johnson operates in the healthcare sector through two main segments: Innovative Medicine and MedTech [4] - The Innovative Medicine segment addresses various therapeutic areas, including oncology and infectious diseases, while the MedTech segment focuses on a wide range of medical devices [4]

Core Insights - GeneDx Holdings (WGS) has announced a strategic partnership with Komodo Health to integrate its Infinity platform with real-world patient insights, enhancing the understanding of rare diseases [1][8] - This collaboration is expected to significantly increase the utility and monetization potential of GeneDx's data assets, positioning the company as a key partner in the rare disease market [2] Partnership Details - The partnership combines GeneDx's genomic and phenotypic data with Komodo's Healthcare Map, which tracks healthcare journeys of over 330 million de-identified patients [9] - The integration aims to provide a longitudinal view of rare diseases, linking genetic data with claims-based care patterns to improve patient management and treatment insights [9][10] Market Impact - Following the announcement, WGS shares remained flat in after-market trading, but have increased by 64.3% over the past six months, outperforming the industry growth of 12.7% and the S&P 500's 14.1% [3] - GeneDx currently has a market capitalization of $3.91 billion [6] Long-term Prospects - The partnership is expected to enhance GeneDx's genomic database, making it more commercially valuable and attractive to biopharma companies [4] - By linking genetic insights with real-world outcomes, GeneDx can support drug discovery, clinical trials, and payer discussions, potentially leading to recurring partnerships and durable revenue growth [4] Industry Context - The global rare diseases treatment market is projected to grow from $216.24 billion in 2024 to $374.39 billion by 2030, with a compound annual growth rate (CAGR) of 11.6% from 2025 to 2030 [12]